Anthony Digiandomenico
CIK 1083544 · Co-Founder · last filed 2026-10-19
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRVB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ANN ARBOR, MI 48105
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXOZ | Director | 3,808,476 | $3.75 | $14.28M | $0 | 1 | 2026-10-19 |
| CLIR | Director | — | $2.30 | — | $0 | 3 | 2026-10-02 |
| NDRA | Director | 136,589 | $4.82 | $658.4K | $100.0K | 6 | 2026-01-23 |
| MDBH | Co-Founder | 95,699 | $1.55 | $148.3K | $78.7K | 17 | 2025-08-08 |
| ENDRA Life Sciences Inc. (NDRAW) Delisted | Director | 382,012 | $0.03 | $11.5K | $16.9K | 17 | 2022-03-30 |
| Provention Bio, Inc. (PRVB) Delisted | Director | 520,712 | $24.98 | $13.01M | $1.08M | 18 | 2019-12-06 |
| CUE | Director | 1,000 | $18.45 | $18.4K | $275.5K | 7 | 2019-01-04 |
| Charlie's Holdings, Inc. (BZI.WS.B) Delisted | Director | — | — | — | $0 | 2 | 2008-08-22 |
Recent Filings · Page 3 of 8
75 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-07 | MDBH | Buy (P) | +16 | $100 | EDGAR |
| 2024-12-30 | MDBH | Buy (P) | +355 | $2.2K | EDGAR |
| 2024-12-23 | MDBH | Buy (P) | −355 | -$2.2K | EDGAR |
| 2024-12-20 | MDBH | Exer (M) | +50,000 | $340.5K | EDGAR |
| 2024-12-20 | MDBH | Buy (P) | −3,693 | -$23.0K | EDGAR |
| 2024-02-23 | NDRA | Grant (A) | — | $0 | EDGAR |
| 2023-05-03 | NDRA | Buy (P) | +83,333 | $100.0K | EDGAR |
| 2023-02-01 | NDRA | Grant (A) | — | $0 | EDGAR |
| 2022-03-30 | ENDRA Life Sciences Inc. (NDRAW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-04 | ENDRA Life Sciences Inc. (NDRAW) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.